[In vitro studies of pancreatic enzyme substitution].
In-vitro activity of 14 commercial pancreatin preparations, commonly used in the Federal Republic of Germany, were tested. All had been declared by their manufacturers to contain more than 6000 FIP (Fédération International Pharmaceutique) units of lipase and to be acid resistant. The declared lipase and amylase amounts were found to be present in 11 of the 14 preparations. Three of the 14 preparations, said to be acid resistant were found not to be so in buffer with falling pH values between 4.0 and 2.5, so that there occurred an, at times marked, loss of enzyme activity. Most noticeable was the poor solubility of most preparations at pH 6.6. Only three of the 14 liberated their total enzyme content within 60 minutes, as they should for theoretical reasons, based on the relatively short duodeno-cecal transit time.
D000681:Amylases / Q000032:analysis / Q000592:standards; D001963:Bromelains / Q000032:analysis / Q000592:standards; D003685:Dehydrocholic Acid / Q000032:analysis / Q000592:standards; D004129:Dimethylpolysiloxanes / Q000032:analysis / Q000592:standards; D004338:Drug Combinations / Q000032:analysis / Q000592:standards; D006863:Hydrogen-Ion Concentration; D008049:Lipase / Q000032:analysis / Q000592:standards; D010184:Pancreatic Extracts / Q000032:analysis / Q000592:standards*; D010194:Pancreatin / Q000032:analysis / Q000592:standards; D012995:Solubility; D014357:Trypsin / Q000032:analysis / Q000592:standards
D004129:Dimethylpolysiloxanes; D004338:Drug Combinations; C002762:Nutrizym; D010184:Pancreatic Extracts; C007844:Gillazym; D010194:Pancreatin; D001963:Bromelains; D008049:Lipase; D000681:Amylases; D014357:Trypsin; D003685:Dehydrocholic Acid
In-vitro-Untersuchungen zur Pankreasenzymsubstitution.